<DOC>
	<DOCNO>NCT00001338</DOCNO>
	<brief_summary>This prospective , randomized Phase III trial FLAC chemotherapy GM-CSF versus PIXY321 advance breast cancer . The primary endpoint study duration thrombocytopenia time recovery platelet 50,000/microliters . Other clinical endpoint include depth duration leukopenia , neutropenia , anemia , platelet RBC transfusion requirement , number document instance sepsis hospitalization fever neutropenia . Laboratory correlate include detailed evaluation effect circulate hematopoietic progenitor cell GM-CSF PIXY321 potential effect agent bone marrow micro-environment . After 5 cycle FLAC GM-CSF versus PIXY321 , patient treat 5 cycle 96 hour infusional taxol . The goal part study assess toxicity feasibility administer infusional taxol follow dose-intensive FLAC chemotherapy .</brief_summary>
	<brief_title>A Prospective , Randomized , Phase III Trial FLAC ( 5-Fluorouracil , Leucovorin , Adriamycin , Cytoxan ) Chemotherapy With GM-CSF ( Granulocyte-Macrophage Colony-Stimulating Factor ) Versus PIXY 321 Advanced Breast Cancer</brief_title>
	<detailed_description>This prospective , randomized Phase III trial FLAC chemotherapy GM-CSF versus PIXY321 advance breast cancer . The primary endpoint study duration thrombocytopenia time recovery platelet 50,000/microliters . Other clinical endpoint include depth duration leukopenia , neutropenia , anemia , platelet RBC transfusion requirement , number document instance sepsis hospitalization fever neutropenia . Laboratory correlate include detailed evaluation effect circulate hematopoietic progenitor cell GM-CSF PIXY321 potential effect agent bone marrow micro-environment . After 5 cycle FLAC GM-CSF versus PIXY321 , patient treat 5 cycle 96 hour infusional taxol . The goal part study assess toxicity feasibility administer infusional taxol follow dose-intensive FLAC chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients Stage IV ( metastatic ) breast cancer histologicallyproven diagnosis . Measurable , evaluable Stage III patient , Stage II patient 4 node positive , Stage IV NED ( evidence disease ) patient . Patients prior radiation therapy provide 20 % bone marrow irradiate . Patients receive less equal 360mg/m2 Adriamycin adjuvant therapy . Patients must previously untreated chemotherapy metastatic disease . There must history previous malignancy except cured nonmelanoma skin cancer ( basal squamous cell carcinoma ) , cervical cancer situ , past malignancy inactive 5 year . Performance status ( Karnofsky scale ) must great 70 ; ECOG 02 . Absolute granulocyte count great 1500 microliters platelet count great 100,000/mm3 . Liver function test ( SGOT , total bilirubin ) less 2X upper limit normal unless evidence hepatic involvement tumor . Serum creatinine le 1.7 creatinine clearance great 45 ml/min . Patients must great equal 18 year age . The patient must able give informed consent , return NCI treatment adequate followup period protocol require . No patient poor medical psychiatric risk nonmalignant systemic disease would preclude subjected treatment protocol . Patients currently require therapy cardiac arrhythmia , congestive heart failure , coronary artery disease . Patients receive prior Adriamycin history cardiac disease must LVEF great 45 percent MUGA . No history CNS metastasis , know seizure disorder . No allergy study medication . No pregnant lactate woman . No patient require ongoing therapy asthma . No patient bleed disorder study entry patient require chronic anticoagulation . No patient active infection know HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Fusion Protein</keyword>
</DOC>